BAGSVAERD, Denmark, Dec. 23, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m2) or who are overweight (BMI =>27 kg/m2) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.

For further information

Media:    
Mike Rulis +45 3079 3573mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316kiau@novonordisk.com
Investors:    
Kasper Roseeuw Poulsen +45 3079 4303krop@novonordisk.com
Melanie Raouzeos +45 3075 3479mrz@novonordisk.com
Daniel Bohsen +45 3079 6376dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567fdni@novonordisk.com

Company announcement No 77 / 2014

Company announcement No 77 / 2015 http://hugin.info/2013/R/1882081/663986.pdf

HUG#1882081